Liu Zhenguo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8015540/publications.pdf

Version: 2024-02-01

840585 552653 26 867 11 26 citations h-index g-index papers 26 26 26 1518 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	An Overview of Pickering Emulsions: Solid-Particle Materials, Classification, Morphology, and Applications. Frontiers in Pharmacology, 2017, 8, 287.	1.6	481
2	Lipopolyplex for Therapeutic Gene Delivery and Its Application for the Treatment of Parkinson's Disease. Frontiers in Aging Neuroscience, 2016, 8, 68.	1.7	46
3	Influence of the COVID-19 Pandemic on Quality of Life of Patients with Parkinson's Disease. Parkinson's Disease, 2020, 2020, 1-6.	0.6	40
4	Exploring the association between Cerebral smallâ€vessel diseases and motor symptoms in Parkinson's disease. Brain and Behavior, 2019, 9, e01219.	1.0	36
5	Developments in human growth hormone preparations: sustained-release, prolonged half-life, novel injection devices, and alternative delivery routes. International Journal of Nanomedicine, 2014, 9, 3527.	3.3	35
6	Risk Score to Predict Hospital-Acquired Pneumonia After Spontaneous Intracerebral Hemorrhage. Stroke, 2014, 45, 2620-2628.	1.0	35
7	The Use of Integrative Therapies in Patients with Amyotrophic Lateral Sclerosis in Shanghai, China. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-6.	0.5	26
8	A survey of subjective constipation in Parkinson's disease patients in shanghai and literature review. BMC Neurology, 2018, 18, 29.	0.8	21
9	CARD9 Signaling, Inflammation, and Diseases. Frontiers in Immunology, 2022, 13, 880879.	2.2	16
10	Non-motor symptoms in Chinese Parkinson's disease patients. Journal of Clinical Neuroscience, 2014, 21, 751-754.	0.8	15
11	Changes in surface expression of N-methyl-D-aspartate receptors in the striatum in a rat model of Parkinson's disease. Drug Design, Development and Therapy, 2014, 8, 165.	2.0	14
12	The CB1 cannabinoid receptor agonist reduces L-DOPA-induced motor fluctuation and ERK1/2 phosphorylation in 6-OHDA-lesioned rats. Drug Design, Development and Therapy, 2014, 8, 2173.	2.0	12
13	Clinical markers of neurodegeneration in Chinese patients with idiopathic rapid eye movement sleep behavior disorder. Clinical Neurology and Neurosurgery, 2016, 150, 105-109.	0.6	9
14	Levodopa/Benserazide Loaded Microspheres Alleviate L-dopa Induced Dyskinesia through Preventing the Over-Expression of D1R/Shp- $2/ERK1/2$ Signaling Pathway in a Rat Model of Parkinson's Disease. Frontiers in Aging Neuroscience, 2017, 9, 331.	1.7	9
15	Multiple Evidences for Association between Cognitive Impairment and Dysglycemia in Parkinson's Disease: Implications for Clinical Practice. Frontiers in Aging Neuroscience, 2017, 9, 355.	1.7	9
16	Determinants of diagnostic latency in Chinese people with Parkinson's disease. BMC Neurology, 2019, 19, 120.	0.8	9
17	Wearing-off Identification in Parkinson's Disease: The shapd-woq Study. Frontiers in Neurology, 2020, 11, 116.	1.1	9
18	Targeting the D1-N-methyl-D-aspartate receptor complex reduces L-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson's rats. Drug Design, Development and Therapy, 2016, 10, 547.	2.0	7

#	Article	IF	CITATIONS
19	The abnormal activation of D1R/Shp-2 complex involved in levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson's rats. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 1779-1786.	1.0	6
20	Prevalence and Clinical Features of FOG in Chinese PD Patients, a Multicenter and Cross-Sectional Clinical Study. Frontiers in Neurology, 2021, 12, 568841.	1.1	6
21	Circulating Endothelial Progenitor Cells Are Preserved in Female Mice Exposed to Ambient Fine Particulate Matter Independent of Estrogen. International Journal of Molecular Sciences, 2021, 22, 7200.	1.8	6
22	L-3,4-Dihydroxyphenylalanine Recovers Circadian Rhythm Disturbances in the Rat Models of Parkinson's Disease by Regulating the D1R-ERK1/2-mTOR Pathway. Frontiers in Aging Neuroscience, 2021, 13, 719885.	1.7	6
23	Effect of Tianqi antitremor granules on behavioral manifestations and expression of G protein-coupled receptor kinase 6 and β-arrestin1 in levodopa-induced dyskinesia in a rat model of Parkinson's disease. Drug Design, Development and Therapy, 2013, 7, 1481.	2.0	5
24	The TLR4 mediated inflammatory signal pathway might be involved in drug resistance in drug-resistant epileptic rats. Journal of Neuroimmunology, 2022, 365, 577802.	1.1	5
25	The clinical value of long - term electroencephalogram (EEG) in seizure - free populations: implications from a cross-sectional study. BMC Neurology, 2020, 20, 88.	0.8	3
26	Shudi Pingchan Decoction combined with repetitive transcranial magnetic stimulation in the treatment of Parkinson's disease with sleep disorders. Traditional Medicine and Modern Medicine, 2020, 03, 85-92.	0.2	1